Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang, I; Brodowicz, T; Ryvo, L; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Messinger, D; Zielinski, C; Lancet Oncol. 2013; 14(2):125-133

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

Gaidzik, VI; Schlenk, RF; Paschka, P; Stölzle, A; Späth, D; Kuendgen, A; von Lilienfeld-Toal, M; Brugger, W; Derigs, HG; Kremers, S; Greil, R; Raghavachar, A; Ringhoffer, M; Salih, HR; Wattad, M; Kirchen, HG; Runde, V; Heil, G; Petzer, AL; Girschikofsky, M; Heuser, M; Kayser, S; Goehring, G; Teleanu, MV; Schlegelberger, B; Ganser, A; Krauter, J; Bullinger, L; Döhner, H; Döhner, K; Blood. 2013; 121(23):4769-4777

Viral infections and their management in patients with chronic lymphocytic leukemia.

Melchardt, T; Weiss, L; Greil, R; Egle, A; Leuk Lymphoma. 2013; 54(8):1602-1613

Circulating tumor DNA to monitor metastatic breast cancer.

Weiss, L; Hufnagl, C; Greil, R; N Engl J Med. 2013; 369(1): 93

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni, L; Romieu, GH; Lichinitser, M; Serrano, SV; Mansutti, M; Pivot, X; Mariani, P; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Moore, N; Prot, S; Pallaud, C; Semiglazov, V; J Clin Oncol. 2013; 31(14):1719-1725

Azacitidine in patients with WHO-defined AML – results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.

Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Sliwa, T; Egle, A; Linkesch, W; Voskova, D; Angermann, H; Greil, R; J HEMATOL ONCOL. 2013; 6: 32

ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll, B; Görgen, H; Fuchs, M; Pluetschow, A; Eich, HT; Bargetzi, MJ; Weidmann, E; Junghanß, C; Greil, R; Scherpe, A; Schmalz, O; Eichenauer, DA; von Tresckow, B; Rothe, A; Diehl, V; Engert, A; Borchmann, P; J Clin Oncol. 2013; 31(12):1522-1529

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Keil, F; Selzer, E; Berghold, A; Reinisch, S; Kapp, KS; De Vries, A; Greil, R; Bachtiary, B; Tinchon, C; Anderhuber, W; Burian, M; Kasparek, AK; Elsäßer, W; Kainz, H; Riedl, R; Kopp, M; Kornek, G; Eur J Cancer. 2013; 49(2):352-359

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna, J; Sastre, J; Arnold, D; Osterlund, P; Greil, R; Van Cutsem, E; von Moos, R; Viéitez, JM; Bouché, O; Borg, C; Steffens, CC; Alonso-Orduña, V; Schlichting, C; Reyes-Rivera, I; Bendahmane, B; André, T; Kubicka, S; Lancet Oncol. 2013; 14(1):29-37

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma.

Ludwig, H; Viterbo, L; Greil, R; Masszi, T; Spicka, I; Shpilberg, O; Hajek, R; Dmoszynska, A; Paiva, B; Vidriales, MB; Esteves, G; Stoppa, AM; Robinson, D; Ricci, D; Cakana, A; Enny, C; Feng, H; van de Velde, H; Harousseau, JL; J Clin Oncol. 2013; 31(2):247-255